BackAcceleron Pharma Overview

Acceleron Pharma Research & Development

Research & Development expenses for XLRN.

Quarterly R&D Expenses

$59.72M
↑ 46.56% YoY

As of Sep 30, 2021

Annual R&D Expenses (TTM)

$230.40M
↑ 39.26% YoY

Trailing 12 months ending Sep 30, 2021

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin